Radiation Oncology/Therapy: Page 371

Varian launches Vitesse 2.0 system
By AuntMinnie.com staff writers
Radiation therapy firm Varian Medical Systems this week launched Vitesse 2.0, a new ultrasound-guided brachytherapy treatment planning system.
April 2, 2006
VisualSonics adds molecular imaging to Vevo 770
By AuntMinnie.com staff writers
Microimaging ultrasound developer VisualSonics is introducing new molecular imaging capabilities for its Vevo 770 microultrasound system at this week's American Association for Cancer Research (AACR) meeting in Washington, DC.
April 2, 2006
CEUS aids differentiation of small liver lesions
By Erik L. Ridley
Contrast-enhanced ultrasound (CEUS) can help diagnose indeterminate small hepatic lesions, according to researchers from the University of California, San Diego. They conducted a study to assess CEUS' accuracy and role in diagnosing small lesions that were indeterminate on CT and/or MRI, and presented their findings at the recent American Institute of Ultrasound in Medicine (AIUM) meeting.
April 2, 2006
Elekta buys BMEI
By AuntMinnie.com staff writers
Swedish radiation oncology firm Elekta of Stockholm has inked a deal to buy 80% of the equity of Chinese radiation therapy equipment supplier BMEI.
March 30, 2006
OnCURE buys four Florida centers
By AuntMinnie.com staff writers
Outpatient radiation therapy provider OnCURE Medical of Newport Beach, CA, has expanded its operations in Florida by acquiring four cancer therapy centers.
March 30, 2006
ART launches preclinical imaging agents
By AuntMinnie.com staff writers
Canadian optical molecular imaging developer ART Advanced Research Technologies launched a new line of biomarker products, called Fenestra, at the American Association for Cancer Research (AACR) meeting in Washington, DC, this week.
March 30, 2006
NAS opens $4 million credit line
By AuntMinnie.com staff writers
Radiation therapy firm North American Scientific (NAS) of Chatsworth, CA, has opened a revolving line of credit worth up to $4 million.
March 30, 2006
CEUS outshines three-phase CT in assessing HCC TACE response
By Erik L. Ridley
Contrast-enhanced ultrasound (CEUS) is more sensitive than three-phase CT in depicting vascularity in hepatocellular carcinomas (HCCs) treated with transcatheter arterial chemoembolization (TACE), according to an article in the April 2006 Journal of Ultrasound in Medicine.
March 30, 2006
Radiation experiment demonstrates long-term damage to normal tissue
By Shalmali Pal
By selectively irradiating blood vessels, Massachusetts Institute of Technology (MIT) researchers have ascertained at what point healthy tissue starts to degrade after radiation exposure. Their results have implications for radiation therapy and exposure, as well as for the long-term effects of both, the authors said.
March 30, 2006
Limiting scan range cuts dose, boosts throughput in melanoma PET/CT
By Jonathan S. Batchelor
ORLANDO, FL - The current PET/CT protocol of scanning all melanoma patients from the crown of the head to the soles of the feet, including dedicated brain studies, may be providing little clinical value and putting patients on the gantry longer than needed, according to a study from the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).
March 29, 2006
Fluke debuts pain management line
By AuntMinnie.com staff writers
The Radiation Management Services unit of Fluke Biomedical has introduced a pain management suite of products.
March 28, 2006
Rising serum markers trigger first-line PET investigation
By Jonathan S. Batchelor
ORLANDO, FL - The post-therapy cancer protocol at many institutions is to watch and wait. If patients manifest elevated serum tumor markers such as S100 or carcinoembryonic antigen (CEA) during this follow-up period, conventional diagnostic methods call for the use of anatomic imaging first, then molecular imaging if necessary. A group in the Netherlands has flipped the imaging order, using PET as the primary imaging modality for occult tumors.
March 28, 2006
Previous Page
Page 371 of 469
Next Page